Peri-procedural anticoagulation in patients with end-stage kidney disease undergoing atrial fibrillation ablation: results from the multicentre end-stage kidney disease–atrial fibrillation ablation registry
EP Europace · 2023
DOI: 10.1093/europace/euad056 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift EP Europace, 2023. Verfasst von Tasuku Yamamoto und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Yushima 1-5-45, Bunkyo-ku, Tokyo 113-8510, Japan. Hauptthemen laut MEDLINE: Atrial Fibrillation, Thromboembolism, Kidney Failure, Chronic, Catheter Ablation. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Aims
The optimal anticoagulation regimen in patients with end-stage kidney disease (ESKD) undergoing atrial fibrillation (AF) catheter ablation is unknown. We sought to describe the real-world practice of peri-procedural anticoagulation management in patients with ESKD undergoing AF ablation. Methods and results Patients with ESKD on haemodialysis undergoing catheter ablation for AF in 12 referral centres in Japan were included. The international normalized ratio (INR) before and 1 and 3 months after ablation was collected. Peri-procedural major haemorrhagic events as defined by the International Society on Thrombosis and Haemostasis, as well as thromboembolic events, were adjudicated. A total of 347 procedures in 307 patients (67 ±9 years, 40% female) were included. Overall, INR values were grossly subtherapeutic [1.58 (interquartile range: 1.20–2.00) before ablation, 1.54 (1.22–2.02) at 1 month, and 1.22 (1.01–1.71) at 3 months]. Thirty-five patients (10%) suffered major complications, the majority of which was major bleeding (19 patients; 5.4%), including 11 cardiac tamponade (3.2%). There were two peri-procedural deaths (0.6%), both related to bleeding events. A pre-procedural INR value of 2.0 or higher was the only independent predictor of major bleeding [odds ratio, 3.3 (1.2–8.7), P = 0.018]. No cerebral or systemic thromboembolism occurred.
Conclusion
Despite most patients with ESKD undergoing AF ablation showing undertreatment with warfarin, major bleeding events are common while thromboembolic events are rare.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Yushima 1-5-45, Bunkyo-ku, Tokyo 113-8510, Japan.
- Department of Cardiology, Yokosuka Kyosai Hospital, Yonegahama-dori 1-16, Yokosuka-shi, Kanagawa 238-8558, Japan.
- Department of Cardiology, Japanese Red Cross Saitama Hospital, Shintoshin 1-5, Chuo-ku, Saiatama-shi, Saitama 330-8553, Japan.
- Cardiovascular Division, Tsuchiura Kyodo Hospital, Otsuno 4-1-1, Tsuchiura-shi, Ibaraki 300-0028, Japan.
- Department of Cardiology, Kameda Medical Center, Higashicho 929, Kamogawa-shi, Chiba 296-8602, Japan.
- Department of Cardiology, University of Fukui Hospital, Shimoaizuki 2303, Matsuoka, Eiheiji-cho, Yoshida-gun, Fukui 910-1193, Japan.
ORCID-Profile: Tasuku Yamamoto, Shinsuke Miyazaki, Yasuaki Tanaka, Toshikazu Kono, Tadanori Nakata, Akira Mizukami, Daisetsu Aoyama, Hirofumi Arai, Yuta Taomoto, Tomoki Horie, Rintaro Hojo, Kento Yabe, Kikou Akiyoshi, Nobutaka Kato, Yuichi Ono, Seiji Fukamizu, Yasutoshi Nagata, Yasuteru Yamauchi, Hiroshi Tada, Hitoshi Hachiya, Tetsuo Sasano
Zitieren
APA
Yamamoto, T., Miyazaki, S., Tanaka, Y., Kono, T., Nakata, T., Mizukami, A., Aoyama, D., Arai, H., Taomoto, Y., Horie, T., Hojo, R., Kawamoto, S., Yabe, K., Akiyoshi, K., Kato, N., Ono, Y., Suzuki, A., Fukamizu, S., Nagata, Y., …, & Sasano, T. (2023). Peri-procedural anticoagulation in patients with end-stage kidney disease undergoing atrial fibrillation ablation: results from the multicentre end-stage kidney disease–atrial fibrillation ablation registry. EP Europace. https://doi.org/10.1093/europace/euad056
Vancouver
Yamamoto T, Miyazaki S, Tanaka Y, Kono T, Nakata T, Mizukami A, et al. Peri-procedural anticoagulation in patients with end-stage kidney disease undergoing atrial fibrillation ablation: results from the multicentre end-stage kidney disease–atrial fibrillation ablation registry. EP Europace. 2023. doi:10.1093/europace/euad056
BibTeX
@article{Yamamoto2023,
author = {Yamamoto, Tasuku and Miyazaki, Shinsuke and Tanaka, Yasuaki and Kono, Toshikazu and Nakata, Tadanori and Mizukami, Akira and Aoyama, Daisetsu and Arai, Hirofumi and Taomoto, Yuta and Horie, Tomoki and Hojo, Rintaro and Kawamoto, Shiho and Yabe, Kento and Akiyoshi, Kikou and Kato, Nobutaka and Ono, Yuichi and Suzuki, Atsushi and Fukamizu, Seiji and Nagata, Yasutoshi and Yamauchi, Yasuteru and Tada, Hiroshi and Hachiya, Hitoshi and Inaba, Osamu and Takahashi, Atsushi and Goya, Masahiko and Sasano, Tetsuo},
title = {Peri-procedural anticoagulation in patients with end-stage kidney disease undergoing atrial fibrillation ablation: results from the multicentre end-stage kidney disease–atrial fibrillation ablation registry},
journal = {EP Europace},
year = {2023},
doi = {10.1093/europace/euad056}
}
EUVIMED